CYP2E1 potentiates toxicity in obesity and after chronic ethanol treatment

Drug Metabolism and Drug Interactions

Volumn 27, Issue 3, 2012, Pages 125-144

  Cederbaum, Arthur I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2E1; Ethanol; Obesity; Oxidative stress; S adenosyl methionine; Steatosis

Indexed keywords

3 NITROTYROSINE; ACETONE; ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2E1; INDUCIBLE NITRIC OXIDE SYNTHASE; PYRAZOLE; S ADENOSYLMETHIONINE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC TOXICITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FATTY LIVER; FEMALE; LIVER INJURY; LIVER TOXICITY; MALE; MOUSE; NITROSATIVE STRESS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; WILD TYPE;

ANIMALS; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; ETHANOL; HUMANS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; MICE; MICE, KNOCKOUT; OBESITY; OXIDATIVE STRESS; S-ADENOSYLMETHIONINE;

EID: 84869436697     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0014     Document Type: Review

References (122)

1. Caro AA, Cederbaum AI. Oxidative stress, toxicology and pharmacology of Cyp2E1. Annual Rev Pharmacol Toxicol 2004;44:27-42. (Pubitemid 38263832)
2. Jimenez-Lopez JM, Cederbaum AI. CYP2E1-dependent oxidative stress and toxicity: role in ethanol-induced liver injury. Expert Opinion Drug Metab Toxicol 2001;1:671-85.
3. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993; 2:1-20.
4. Bolt M, Koos PH, Their R. The cytochrome P450 isoenzyme CYP2E1 in the biological processing of industrial chemicals. Int Arch Occup Environ Health 2003;76:174-85.
5. Koop DR. Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J 1992;6:724-30.
6. Song BJ, Cederbaum AI, Koop DR, Ingelman-Sundberg M, Nanji A. Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance. Alcohol Clin Exp Res 1996;20(Suppl):138A- 46A. (Pubitemid 26393979)
7. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000;25:165-75. (Pubitemid 30495308)
8. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005;569:101-10. (Pubitemid 39643260)
9. French SW, Morimoto M, Reitz RC, Koop D, Klopfenstein B, Estes K, et al. Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. J Nutr 1997;127:907S-11S. (Pubitemid 27209466)
10. Castillo T, Koop DR, Kamimura S, Triadafilopoulos G, Tsukamoto H. Role of cytochrome P4502E1 in ethanol, carbon tetrachloride and iron-dependent microsomal lipid peroxidation. Hepatology 1992;16:992-6.
11. Morimoto M, Zern MA, Hagbjork AL, Ingelman-Sundberg M, French SW. Fish oil, alcohol and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Biol Med 1994;207: 197-205. (Pubitemid 24323768)
12. Nanji AA, Zhao S, Sadrzadeh SM, Dannenberg AJ, Tahan SR, Waxman DJ. Markedly enhanced cytochrome P4502E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res 1994;18: 1280-5. (Pubitemid 24345545)
13. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001;15:1335-49. (Pubitemid 32531812)
14. Morimoto M, Hagbjork AL, Wan YJ, Fu PC, Clot P, Albano E, et al. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology 1995;21:1610-7.
15. Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, et al. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med 2000;224:302-8. (Pubitemid 30643509)
16. Raucy JL, Lasker JM, Kramer JC, Salazer DE, Lieber CS, Corcoran GB. Induction of P-450IIE1 in the obese rat. Mol Pharmacol 1991;39:275-80.
17. Yun Y, Casazza JP, Sohn DH, Veech RL, Song BJ. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet. Mol Pharmacol 1992;41:474-9.
18. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002;35:263-73. (Pubitemid 34106364)
19. Hong JY, Pan J, Gonzalez FJ, Gelboin HV, Yang CS. The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem Biophys Res Commun 1987;142:1077-83. (Pubitemid 17021143)
20. Weltman MD, Farrell GC, Liddle C. Increased hepatocytes CYP2E1 expression in a rat nutritional model of hepatic steatosis and inflammation. Gastroenterology 1996;111:1645-53. (Pubitemid 26404230)
21. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-33. (Pubitemid 28041545)
22. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-5. (Pubitemid 36182434)
23. Zimmermann-Belsing T, Feldt-Rasmussen U. Obesity: the new worldwild epidemic threat to general health and our complete lack of effective treatment. Endocrinolgy 2004;145:1501-2. (Pubitemid 38402352)
24. McClain CJ, Mokshagundam SP, Barve SS, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004;34:67-79. (Pubitemid 40163990)
25. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-10. (Pubitemid 43049850)
26. Pelleymounter MA, Cullen Mj, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
27. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001;293:1673-7. (Pubitemid 32807849)
28. Hirosumi J, Tuncman G, Chang L, Gorgun, CZ, Usyal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6. (Pubitemid 35398190)
29. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005;33:138-44. (Pubitemid 41799792)
30. Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume EP, Resnick MB, et al. Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell specific UCP2 expression. Hepatology 2006;44:592-601. (Pubitemid 44433715)
31. Dey A, Cederbaum AI. Induction of cytochrome P4502E1 produces liver injury in ob/ob mice. Hepatology 2007;45:1355-65. (Pubitemid 46918319)
32. Koop DR, Casazza JP. Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J Biol Chem 1985;260:13607-12. (Pubitemid 16192315)
33. Winters DK, Cederbaum AI. Time course characterization of the induction of cytochrome P-450 2E1 by pyrazole and 4-methylpyrazole. Biochim Biophys Acta 1992;1117:15-24.
34. McKim SE, Gabele E, Isayama F, Lambert JC, Wheeler MD, Connor HD, et al. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003;125:1834-44. (Pubitemid 37500447)
35. Lu SC, Tsukamoto H, Mato JM. Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 2002;27:155-62. (Pubitemid 34876916)
36. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 2002;27:173-7. (Pubitemid 34876919)
37. Lu SC, Huang ZZ, Yang H, Mato JM, Avila MA, Tsukamoto H. Changes in methionine adenosyltransferase and S-adenosylmethionine homeostasis in alcoholic rat liver. Am J Physiol GI Liver Physiol 2000;278:G178-85. (Pubitemid 30612697)
38. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-Adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265-80. (Pubitemid 27224439)
39. Cravo ML, Camilo ME. Hyperhomocysteinemia in chronic alcoholism: relations to folic acid and vitamins B(6) and B(12) status. Nutrition 2000;16:296-302. (Pubitemid 30176058)
40. Bailey SM, Robinson G, Pinner A, Chamlee L, Ulasova E, Pompilius M, et al. Adenosylmethioine prevents chronic - induced mitochondrial dysfunction in the rat liver. Am J Physiol GI Liver Physiol 2006;291:G857-67. (Pubitemid 44772012)
41. Wang X, Cederbaum AI. S-Adenosyl-L-methionine attenuates hepatotoxicty induced by agonistic Fas antibody following CYP2E1 induction in mice. J Pharmacol Exp Ther 2006;317: 44-2.
42. Song Z, Zhou Z, Chen T, Hill D, Kang J, Barve S, et al. S-Adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicty in mice. J Nutr Biochem 2003;14:591-7. (Pubitemid 37239012)
43. Dey A, Caro AA, Cederbaum AI. S-Adenosylmethionine protects ob/ob mice from CYP2E1-mediated liver injury. Am J Physiol GI Liver Physiol 2007;293:G91-103.
44. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-62. (Pubitemid 27136914)
45. Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxininduced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001;281:G382-92.
46. Purohit V, Gao B, Song BJ. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res 2009;33:191-205.
47. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol GI Liver Physiol 2004;287:G1-6. (Pubitemid 38802112)
48. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004;34:39-43.
49. Crabb DW, Liangpunsaku S. Alcohol and lipid metabolism. J Gastroent Hepatol 2006;21:S56-60. (Pubitemid 44266552)
50. Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab 2008;295:E10-6.
51. Kono H, Bradford BU, Yin M, Sulik KK, Koop DR, Peters JM, et al. CYP2E1 is not involved in early-alcohol-induced liver injury. Am J Physiol 1999;277:G1259-67. (Pubitemid 30046029)
52. Wan YY, Cai Y, Li J, Yuan Q, French B, Gonzalez FJ, et al. Regulation of peroxisome proliferator activated receptor alpha-mediated pathways in alcohol fed cytochrome P450 2E1 deficient mice. Hepatol Res 2001;19:117-30. (Pubitemid 32097937)
53. Song, BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989;264:3568-72. (Pubitemid 19063417)
54. Lieber CS, DeCarli LM. Hepatic microsomal ethanol-oxidizing system. In vitro characteristics and adaptive properties in vivo. J Biol Chem 1970;245:2505-12.
55. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006;34:57-63. (Pubitemid 43091877)
56. Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 2000;268:337-44. (Pubitemid 30119623)
57. Carmial-Haggai M, Cederbaum AI, Nieto N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 2003;125:1818-33. (Pubitemid 37500446)
58. Zamora R, Vodovotz Y, Allarcon L, Betten B, Loughran PA, Aulak KS, et al. Nitric oxide from the inducible nitric oxide synthase (iNOS) increases the expression of cytochrome P4502E1 in iNOS-null hepatocytes in the absence of inflammatory stimuli. Arch Biochem Biophys 2001;390:287-94. (Pubitemid 32568490)
59. Fujimoto M, Shimiizu N, Kunii K, Martyn JA, Ueki K, Kaneki M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 2005;54:1340-8. (Pubitemid 40586662)
60. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92. (Pubitemid 32246672)
61. Perez-Carreras M, Del Hovo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007. (Pubitemid 37221683)
62. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, del Hoyo P, Colina F, Munoz-Yague T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006;44:581-91. (Pubitemid 44433714)
63. Nieto N, Mari M, Cederbaum AI. Cytochrome P450 2E1 responsiveness in the promoter of glutamate-cysteine catalytic subunit. Hepatology 2003;37:96-106. (Pubitemid 36042150)
64. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
65. Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS. Altered tumor necrosis factor alpha (TNF alpha) processing and increased expression of transmembrane TNF alpha in obesity. Diabetes 2002;51:1876-83. (Pubitemid 34564301)
66. Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2005;2:85-93.
67. Yang S, Zhu H, Li Y, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-relates oxidant stress. Arch Biochem Biophys 2000;378:259-68. (Pubitemid 30397626)
68. Shivapurkar N, Poirier LA. Tissue levels of S-adenosylmethionine and S-adenosylhomocysteine in rats fed methyl-deficient amino acid defined diets for one to five weeks. Carcinogenesis 1983;4:1051-7. (Pubitemid 13014559)
69. Koteish A, Diehl AM. Animal models of steatohepatitis. Best Prac Res Clin Gastroenterol 2002;16:679-90.
70. Duce AM, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988;8:65-8. (Pubitemid 18092060)
71. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
72. Chawla RK, Watson WH, Eastin CE, Lee Ey, Schmidt J, McClain CJ. S-Adenosylmethioinine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am J Physiol GI Liver Physiol 1998;275:G125-9.
73. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999;13:1169-83. (Pubitemid 29300363)
74. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 2002;277:9853-64. (Pubitemid 34968090)
75. Mari M, Cederbaum AI. Induction of catalase, alpha, and microsomal glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress. Hepatology 2001;33:652-61. (Pubitemid 32185228)
76. Gong P, Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 2006;43:144-53. (Pubitemid 43733601)
77. Lu Y, Zhuge J, Wang X, Bai J, Cederbaum AI. Cytochrome P4502E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008;47:1483-94. (Pubitemid 351702732)
78. Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcoholinduced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knockin mice. Free Radical Biol Med 2010;49:1406-16.
79. Lee SS, Buter JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996;271:12063-7. (Pubitemid 26157285)
80. Cheung C, Yu AM, Ward JM, Krausz JW, Akiyama TE, Feigenbaum L, et al. The CYP2E1-humanized transgenic mouse: role of CYP2E1 in acetaminophen hepatoxicity. Drug Metab Disp 2005;33:449-57. (Pubitemid 40279947)
81. Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008;327:288-99.
82. Lieber CS, DeCarli LM. Animal models of chronic ethanol toxicity. Methods Enzymol 1994;233:585-94.
83. Liu H, Lo CR, Czaja, MJ. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 2002;35: 772-8. (Pubitemid 34258370)
84. Czaja MJ. The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 2003;284:G875-9. (Pubitemid 36597328)
85. Henderson NC, Pollock K, Frew J, Mackinnon AC, Flavell RA, Davis R, et al. Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 2001;56: 982-90.
86. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006;131: 165-78. (Pubitemid 44015744)
87. Bae MA, Pie JE, Song BJ. Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway. Mol Pharmacol 2001;60:847-56. (Pubitemid 32900268)
88. Liu H, Jones BE, Bradham C, Czaja MJ. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2002;282:G257-66. (Pubitemid 34651682)
89. Wu D, Cederbaum AI. Cytochrome p4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice. Hepatology 2008;47:1005-17. (Pubitemid 351449692)
90. Lu Y, Wang X, Cederbaum AI. Lipopolysaccharide-induced liver injury in rats treated with the CYP2E1 inducer pyrazole. Am J Physiol Gastrointest Liver Physiol 2005;289:G308-19. (Pubitemid 41022758)
91. Lu Y, Cederbaum AI. Enhancement by pyrazole of lipopolysaccharide- induced liver injury in mice: role of cytochrome P450 2E1 and 2A5. Hepatology 2006;44:263-74. (Pubitemid 44049158)
92. Diluzio NR. Prevention of the acute ethanol-induced fatty liver by the simultaneous administration of antioxidants. Life Sci 1964;3:113-8.
93. Wheeler MD, Nakagami M, Bradford BU, Uesugi T, Mason RP, Connor HD, et al. Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. J Biol Chem 2001;276:36664-72.
94. Cohen JI, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 2010;139:664-74.
95. Fisher M, You M, Matsumoto M, Crabb DW. PPAR agonist treatment reverses PPAR dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003;278:27997-8004.
96. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor protects against alcohol-induced liver damage. Hepatology 2004;40:972-80. (Pubitemid 39288131)
97. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-regulated genes and is ameliorated by PPAR-activation. J Pharmacol Exp Ther 2004;310:417-24. (Pubitemid 38812737)
98. Fujino G, Noguchi T, Matsuzawa A, Yamauchi S, Saitoh M, Takeda K, et al. Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1. Mol Cell Biol 2007;27:8152-63. (Pubitemid 350234230)
99. Liu H, Nishito H, Ichijo H, Kyriaki JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 2000;20:2198-208. (Pubitemid 30123835)
100. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-61. (Pubitemid 40343077)
101. Morgan K, French SW, Morgan TR. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002;36:122-34. (Pubitemid 34700769)
102. Butura A, Nilsson K, Morgan K, Morgan TR, French S, Johanssson I, et al. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 2008;50:572-83.
103. Bai J, Cederbaum AI. Adenovirus-mediated expression of CYP2E1 produces liver toxicity in mice. Toxicol Sci 2006;91:365-71. (Pubitemid 43827289)
104. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010;391:1249-64.
105. Yin M, Wheeler MD, Kono H, Bradford BU, Galluchi RM, Luster MI, et al. Essential role of tumor necrosis factor in alcoholinduced liver injury. Gastroent 1999;117:942-52. (Pubitemid 29468238)
106. Venkatesan S, Ward RJ, Peters TJ. Effect of chronic ethanol feeding on the hepatic secretion of very low density lipoproteins. Biochim Biophy Acta 1988;960:61-6.
107. Galli A, Pinaire J, Fisher M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of PPARa is inhibited by ethanol metabolism. A novel mechanism of the development of ethanol-induced fatty liver. J Biol Chem 2001;276:68-75. (Pubitemid 32050290)
108. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of alcohol in the liver. Gastroenterology 2004;127:1798-808. (Pubitemid 39575858)
109. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099-112. (Pubitemid 43816952)
110. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G833-42.
111. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100. (Pubitemid 38056380)
112. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005;42: 568-77. (Pubitemid 41233649)
113. Shen Z, Liang X, Rogers CQ, Rideout D, You M. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of Rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G364-74.
114. Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MiR-217 promotes ethanol-induced fat accumulation in hepatocytes by down regulating SIRT1. J Biol Chem 2012;287:9817-26.
115. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L, Murr MM, et al. Role of SIRT1 in regulation of LPS- or two ethanol metabolitesinduced TNF production in cultured macrophage cell lines. Am J Physiol GI Liver Physiol 2009;296:G1047-53.
116. You M, Liang X, Ajmo JM, Gene C. Involvement of mammalian Sirtuin1 in the action of ethanol in the liver. Am J Physiol GI Liver Physiol 2008;294:G892-8. (Pubitemid 351520077)
117. Chacko BK, Srivastava A, Johnson MS, Benavides GA, Chang MJ, Ye Y, et al. Mitochondria-targeted ubiquinone (Mito Q) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology 2011;54:153-63.
118. Pritchard MT, McMullen MR, Stavistsky AB, Cohen JI, Lin F, Medof ME, et al. Differential contributions of C3, C5 and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 2007;132:1117-26. (Pubitemid 46440876)
119. French SW. The role of hypoxia in the pathogenesis of alcoholic liver disease. Hepatol Res 2004;29:67-74.
120. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, et al. Hepatocyte specific hypoxia-inducible factor-1 is a determinant of lipid accumulation and liver injury in alcoholinduced steatosis in mice. Hepatology 2011;53: 1528-37.
121. Robin MA, Savage I, Grandperret T, Descatoire V, Pessayre D, Fromenty B. Ethanol increases mitochondrial cytochrome P4502E1 in mouse liver and rat hepatocytes. FEBS Lett 2005;579:6895-902. (Pubitemid 41773706)
122. Knockaert L, Descatoire V, Vadrot N, Fromenty B, Robin MA. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro 2011;25:475-84.